Northwest Biotherapeutics (NWBO) Other Non Operating Income (2010 - 2026)

Northwest Biotherapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• On a quarterly basis, Other Non Operating Income rose 81.54% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 110.66% increase from a year earlier, with the FY2025 full-year figure at -$6.8 million, down 1976.92% from the prior year.
• Other Non Operating Income declined to -$1.3 million in Q1 2026 per NWBO's latest filing, from $8.3 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $8.3 million in Q4 2025 and bottomed at -$19.0 million in Q4 2022.
• The 5-year median for Other Non Operating Income is -$1.7 million (2024), against an average of -$2.7 million.
• Biggest YoY gain for Other Non Operating Income was 593.64% in 2025; the steepest drop was 9935.56% in 2025.
• Year by year, Other Non Operating Income stood at -$19.0 million in 2022, then soared by 51.11% to -$9.3 million in 2023, then surged by 81.86% to -$1.7 million in 2024, then soared by 593.64% to $8.3 million in 2025, then slumped by 116.18% to -$1.3 million in 2026.
• Per Business Quant, the three latest NWBO Other Non Operating Income figures stand at -$1.3 million (Q1 2026), $8.3 million (Q4 2025), and -$1.0 million (Q3 2025).